Unknown

Dataset Information

0

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.


ABSTRACT: Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas.We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer driver mutations were tested for sensitivity to targeted inhibitors in vitro. Associations between genomic alterations and outcomes were analyzed in patients.By 10 months, 8 of 20 IDH1-mutant gliomas developed intracerebral xenografts. All xenografts maintained mutant IDH1 and high levels of 2-hydroxyglutarate on serial transplantation. All xenograft-producing gliomas harbored "lineage-defining" mutations in CIC (oligodendroglioma) or TP53 (astrocytoma), and 6 of 8 additionally had activating mutations in PIK3CA or amplification of PDGFRA, MET, or N-MYC. Only IDH1 and CIC/TP53 mutations were detected in non-xenograft-forming gliomas (P = 0.0007). Targeted inhibition of the additional alterations decreased proliferation in vitro. Moreover, we detected alterations in known cancer driver genes in 13.4% of IDH-mutant glioma patients, including PIK3CA, KRAS, AKT, or PTEN mutation or PDGFRA, MET, or N-MYC amplification. IDH/CIC mutant tumors were associated with PIK3CA/KRAS mutations whereas IDH/TP53 tumors correlated with PDGFRA/MET amplification. Presence of driver alterations at progression was associated with shorter subsequent progression-free survival (median 9.0 vs. 36.1 months; P = 0.0011).A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. Clin Cancer Res; 20(11); 2898-909. ©2014 AACR.

SUBMITTER: Wakimoto H 

PROVIDER: S-EPMC4070445 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto Hiroaki H   Tanaka Shota S   Curry William T WT   Loebel Franziska F   Zhao Dan D   Tateishi Kensuke K   Chen Juxiang J   Klofas Lindsay K LK   Lelic Nina N   Kim James C JC   Dias-Santagata Dora D   Ellisen Leif W LW   Borger Darrell R DR   Fendt Sarah-Maria SM   Vander Heiden Matthew G MG   Batchelor Tracy T TT   Iafrate A John AJ   Cahill Daniel P DP   Chi Andrew S AS  

Clinical cancer research : an official journal of the American Association for Cancer Research 20140408 11


<h4>Purpose</h4>Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas.<h4>Methods</h4>We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer driver mutations were tested for sensitivity to targeted inhibitors in  ...[more]

Similar Datasets

| S-EPMC6826741 | biostudies-literature
| S-EPMC8028475 | biostudies-literature
| S-EPMC5689569 | biostudies-literature
| S-EPMC7145561 | biostudies-literature
| S-EPMC3984548 | biostudies-literature
| S-EPMC6320119 | biostudies-literature
| S-EPMC4483044 | biostudies-literature
| S-EPMC4831574 | biostudies-literature
| S-EPMC5961205 | biostudies-literature